U.S. CDMRP – Prostate Cancer Research Program (PCRP)| Research Funding
Event details
| Date | 21.06.2024 |
| Category | Call for proposal |
Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2024 Prostate Cancer Research Program (PCRP) Awards. Several award programs are available:
- The FY24 PCRP Data Science Award mechanism supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data.
- The Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).
- The Exploration – Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation.
- The Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission.
- The Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research.
Applications to all awards are required to address one or more of the FY24 PCRP Overarching Challenges (listed below).
Funding:
- Data Science Award: $1,000,000
- Early Investigator Research Award: $300,000
- Exploration - Hypothesis Development Award: $150,000
- Idea Development Award: $1,200,000
- Physician Research Award: $750,000
Duration:
- Data Science Award: 1 year
- Early Investigator Research Award: 2 years
- Exploration - Hypothesis Development Award: 2 years
- Idea Development Award: 3 years
- Physician Research Award: 4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible. For the Early Investigator Research Award, Post-doctoral PIs must possess a doctoral degree (or equivalent), and have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training).
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace. Application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline:
- 21 June 2024, 5:00 p.m. Eastern time for the Exploration - Hypothesis Development Award
- 28 June 2024, 5:00 p.m. Eastern time for the Idea Development Award
- 09 August 2024, 5:00 p.m. Eastern time
Full Application Deadline:
- 12 July 2024, 11:59 p.m Eastern Time for the Exploration - Hypothesis Development Award
- 19 July 2024, 11:59 p.m Eastern Time for the Idea Development Award
- 30 August 2024, 11:59 p.m Eastern Time
Further information:
- To find the full program announcements and to start your pre-application see here
- A useful summary of each call can be found here
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
- Grants.gov Funding Opportunity Numbers:
- Data Science Award: HT942524PCRPDSA
- Early Investigator Research Award: HT942524PCRPEIRA
- Exploration - Hypothesis Development Award: HT942524PCRPEHDA
- Idea Development Award: HT942524PCRPIDA
- Physician Research Award: HT942524PCRPPRA
FY24 PCRP Overarching Challenges
- Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer
Applications should aim to understand the impact of prostate cancer on the quality of life of the cancer survivor, their family, their caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness. Studies should consider both short- and long-term quality-of-life outcomes. Areas of particular interest include:
-
- The mental and emotional health of patients and their families/caregivers
- Impact of quality-of-life considerations on decision-making after diagnosis and/or treatment
- Identification of vulnerable groups of patients and their families at great risk of quality-of-life detriments
- Implementation of factors or interventions that improve access to evidence-based care, quality-of-life outcomes, and overall health and wellness
- Develop new treatments or improve upon existing therapies to improve outcomes for patients with lethal prostate cancer
Applications must be directly related to prostate cancer with a high risk of death, including high-risk, localized disease, regional disease, and/or metastatic prostate cancer.
Treatments may address any stage in the continuum of care, including local therapies such as surgery or radiation designed to treat patients with a high risk of death from the disease. Proposed treatments are highly encouraged to consider preserving patient quality of life and not focus only on survival outcomes.
Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions.
(https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).
- Advance health equity and reduce disparities in prostate cancer
Applications must be directly relevant to better understanding and/or reduction of health inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and/or survive prostate cancer.
Applications are encouraged to focus on implementing factors or interventions with the potential to improve access to evidence-based care, quality-of-life outcomes, and overall health and wellness.
Health equity-focused applications will propose research on how patients can attain full potential for health and well-being, taking into consideration physical, mental, or emotional health differences; the impact of race or ethnicity, geography, and environment; as well as lifestyle and socioeconomic differences experienced in high-risk and/or underserved prostate cancer patient populations.
High-risk and/or underserved populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, Veterans, patients with limited access to clinical care and resources (in rural or urban settings), or other populations experiencing barriers to quality healthcare.
- Define the biology of prostate cancer progression to lethal prostate cancer to reduce death
Applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer. The FY24 PCRP also strongly encourages research involving patient-derived materials or specimens related to ongoing or completed clinical trials. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions.
(https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).
Practical information
- General public
- Free